RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
32 hedge funds and large institutions have $1.57M invested in RVL Pharmaceuticals plc Ordinary Shares in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 36 → 32 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
88% less capital invested
Capital invested by funds: $13.5M → $1.57M (-$11.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$182K |
| 2 |
Renaissance Technologies
New York
|
+$111K |
| 3 |
Millennium Management
New York
|
+$71.8K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$21.2K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rovida Advisors
Fort Lauderdale,
Florida
|
-$1.68M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$844K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$625K |
| 4 |
Morgan Stanley
New York
|
-$276K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$156K |
RVLP Hedge Fund Activity: Q3 2023 in Review
32 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q3 2023, worth a combined $1.57M — down 88% from $13.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RVLP and 8 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Blackstone Inc, opening a new position worth an estimated $182K. The largest seller was Rovida Advisors, exiting entirely with an estimated $1.68M sold.
- 32 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q3 2023, down from 36 in Q2 2023.
- Funds reported $1.57M of RVL Pharmaceuticals plc Ordinary Shares stock for Q3 2023, down 88% quarter-over-quarter.
- 8 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q3 2023 and 12 closed out, a net change of -4 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q3 2023 was Blackstone Inc, an estimated $182K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q3 2023 was Rovida Advisors, an estimated $1.68M sold.
Based on aggregated 13F filings for Q3 2023.